CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1438 participants.

Also called NCT04136171

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,438 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04136171
  • EudraCT 2019-002835-27
  • EU CT 2024-514434-20-00
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Poland, Portugal, Puerto Rico, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04136171. Randomized; double masking; primary purpose treatment. Start 2020-03-13 (actual); primary completion 2026-03-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Condition
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Intervention (Drug)
Eplontersen
Intervention (Drug)
Placebo
Lead sponsor
Ionis Pharmaceuticals, Inc. (class: industry)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04136171
Content hash
fb6bec089cb27892e68031367fceb745bb707be854f1f8407635075cce69509c